

# The added value of WES reanalysis in the field of genetic diagnosis: lessons learned from 200 exomes in the Lebanese population

Nadine Jalkh, Sandra Corbani, Zahraa Haidar, Nadine Hamdan, Elias Farah, Joelle Abou Ghoch, Rouba Ghosn, Nabiha Salem, Ali Fawaz, Claudia Djambas Khayat, et al.

# ▶ To cite this version:

Nadine Jalkh, Sandra Corbani, Zahraa Haidar, Nadine Hamdan, Elias Farah, et al.. The added value of WES reanalysis in the field of genetic diagnosis: lessons learned from 200 exomes in the Lebanese population. BMC Medical Genomics, 2019, 12 (1), 10.1186/s12920-019-0474-y. hal-02048914

# HAL Id: hal-02048914 https://amu.hal.science/hal-02048914

Submitted on 25 Feb 2019  $\,$ 

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

https://doi.org/10.1186/s12920-019-0474-y

Jalkh et al. BMC Medical Genomics

**Open Access** 



# The added value of WES reanalysis in the field of genetic diagnosis: lessons learned from 200 exomes in the Lebanese population

(2019) 12:11

Nadine Jalkh<sup>1</sup>, Sandra Corbani<sup>1</sup>, Zahraa Haidar<sup>1</sup>, Nadine Hamdan<sup>1</sup>, Elias Farah<sup>2</sup>, Joelle Abou Ghoch<sup>1</sup>, Rouba Ghosn<sup>1</sup>, Nabiha Salem<sup>1</sup>, Ali Fawaz<sup>3</sup>, Claudia Djambas Khayat<sup>4,5</sup>, Mariam Rajab<sup>6</sup>, Chebl Mourani<sup>4,5</sup>, Adib Moukarzel<sup>4,5</sup>, Simon Rassi<sup>7</sup>, Bernard Gerbaka<sup>4,5</sup>, Hicham Mansour<sup>8</sup>, Malek Baassiri<sup>9</sup>, Rawane Dagher<sup>10</sup>, David Breich<sup>11</sup>, André Mégarbané<sup>12,13</sup>, Jean Pierre Desvignes<sup>14</sup>, Valérie Delague<sup>14</sup>, Cybel Mehawej<sup>1</sup> and Eliane Chouery<sup>1\*</sup>

# Abstract

**Background:** The past few decades have witnessed a tremendous development in the field of genetics. The implementation of next generation sequencing (NGS) technologies revolutionized the field of molecular biology and made the genetic information accessible at a large scale. However, connecting a rare genetic variation to a complex phenotype remains challenging. Indeed, identifying the cause of a genetic disease requires a multidisciplinary approach, starting with the establishment of a clear phenotype with a detailed family history and ending, in some cases, with functional assays that are crucial for the validation of the pathogenicity of a mutation.

**Methods:** Two hundred Lebanese patients, presenting a wide spectrum of genetic disorders (neurodevelopmental, neuromuscular or metabolic disorders, etc.), sporadic or inherited, dominant or recessive, were referred, over the last three and a half years, to the Medical Genetics Unit (UGM) of Saint Joseph University (USJ). In order to identify the genetic basis of these diseases, Whole Exome Sequencing (WES), followed by a targeted analysis, was performed for each case. In order to improve the genetic diagnostic yield, WES data, generated during the first 2 years of this study, were reanalyzed for all patients who were left undiagnosed at the genetic level. Reanalysis was based on updated bioinformatics tools and novel gene discoveries.

**Results:** Our initial analysis allowed us to identify the specific genetic mutation causing the disease in 49.5% of the cases, in line with other international studies. Repeated WES analysis enabled us to increase the diagnostics yield to 56%.

**Conclusion:** The present article reports the detailed results of both analysis and pinpoints the contribution of WES data reanalysis to an efficient genetic diagnosis. Lessons learned from WES reanalysis and interpretation are also shared.

Keywords: High throughput sequencing, Exome, NGS, Mutations, Genetic heterogeneity, Genetic diagnostics, Lebanon

\* Correspondence: eliane.chouery@usj.edu.lb

<sup>1</sup>Unité de Génétique Médicale, Faculté de Médecine, Campus De l'innovation et du sport, Université Saint-Joseph, rue de Damas, Beirut, Lebanon Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

# Background

The identification and characterization of the molecular basis of genetic disorders is crucial for the establishment of a specific diagnosis. This allows the family to benefit from an accurate genetic counseling, the patient to be aware of his disease's prognosis and the physician to implement adequate therapeutic approaches, when possible. The last few years have seen an outstanding improvement in the field of molecular biology [1].

Indeed, the emergence of new high-throughput technologies or Next Generation Sequencing methods (NGS) such as WGS (Whole Genome Sequencing) and WES (Whole Exome Sequencing), has revolutionized the field of genetic diagnosis and made it much more efficient and affordable [2]. While WGS provides a thorough picture of the genome, WES was developed as a practical and cost effective alternative to WGS, targeting only coding regions and canonical splice sites that represent 1–1.5% of the human genome. The rationale behind this approach is that 80–85% of the mutations responsible for Mendelian diseases are located in these regions [3–5].

All these advances are driving NGS from the research field into the clinic. However, data interpretation remains the main challenge especially that thousands of variants of unknown significance are detected in each patient [6, 7].

Here we report the use of WES for genetic diagnostics purposes in 200 Lebanese patients who presented with a wide range of phenotypes, suggesting clinical and genetic heterogeneity. An initial analysis was performed followed, 2 years later, by data reanalysis in order to improve the genetic diagnostic yield. The outcome of WES in the Lebanese population is discussed and lessons learned from this study are shared.

#### Methods

# Clinical samples

From January 2015 to June 2018, 200 patients with genetically heterogeneous disorders were included in our study. They were referred from different Lebanese areas, by private sector and academic physicians. All patients underwent a detailed review of their clinical history and a laboratory evaluation. The most common features of the 200 patients were global developmental delay/intellectual disability, encephalopathy, muscular weakness, failure to thrive and microcephaly.


Approval to conduct the study was obtained from the Ethics Committee of Saint Joseph University, Beirut, Lebanon. All patients, parents or legal guardians signed an informed consent for participation, sample collection and data publication. Peripheral blood was then collected from each individual enrolled in this study and DNA was extracted using the salting out method [8].

## WES analysis

Exon capture and sequencing: The exome was captured using the SureSelect Human All Exons, reagents (Agilent Inc.<sup>®</sup> Santa Clara, CA) according to the manufacturer's standard protocol. The concentration of each library was determined using Agilent's QPCR NGS Library Quantification Kit (G4880A). Samples were pooled prior to sequencing with a final concentration of each sample equal to 10 nM. Sequencing was performed on the Illumina HiSeq2000 platform using TruSeq v3 chemistry.

Mapping and alignment: Reads files (FASTQ) were generated from the sequencing platform via the manufacturer's proprietary software. Reads were aligned to the hg19/b37 reference genome using the Burrows-Wheeler Aligner (BWA) package v0.6.1 [9]. Local realignment of the mapped reads around potential insertion/deletion (Indel) sites was carried out with the Genome Analysis Tool Kit (GATK) v1.6 [10]. Duplicate reads were marked using Picard v1.62. Additional BAM file manipulations were performed with Samtools 0.1.18 [11]. Base quality (Phred scale) scores were recalibrated using GATK's covariance recalibration. SNP and Indel variants called using the GATK Unified Genotyper for each sample [12]. Variants were called using high stringency settings and annotated with VarAFT software 1.61 [13] containing information from dbSNP147 and ExAC (http://exac. broadinstitute.org/). For all patients who were left undiagnosed, reanalysis of vcf files was carried out using VarAFT2.131 and polymorphisms were further filtered using our in-house local database containing more than 300 exomes (Fig. 1).

In terms of functional annotation, we included only protein-altering variants, including truncating variants (stop gain/loss, start loss, or frameshift), missense variants, canonical splice-site variants, inframe indels affecting protein-coding regions, and variants within the intron-exon boundary (ten bases flanking the exonic boundaries). We focused on genotypes absent in our local control data sets. We systematically considered four different genetic models, using stratified European and African Americans in the Exon Variant Server (EVS) for minor allele frequency estimations: (a) germ-line de novo mutations, also absent in the local control populations; (b) recessive homozygous genotypes, which were heterozygous in both parents, never homozygous in controls, with a control allele frequency < 1%; (c) hemizygous X chromosome variants inherited from an unaffected heterozygous mother, with a control allele frequency < 1% and never observed in male controls or homozygous in female controls; and (d) compound heterozygous genotypes in the patient (one variant inherited from each heterozygous parent, with the two variants occurring at different genomic positions within the same gene), for which neither variant was ever homozygous in



controls, and each had a control allele frequency < 1%. For the compound heterozygous genotypes, we further required study of phasing of the two variants. Genotypes meeting these criteria were referred to as "candidate genotypes," with the genes harboring candidate genotypes referred to as "candidate genes" [14].

# Variants confirmation and segregation studies by sanger sequencing

Primers were designed using Primer 3 (http://frodo.wi. mit.edu) and OLIGOS v.9.3, and checked for specificity using BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi). DNA sequences were obtained from UCSC and Genbank databases. Standard PCR reactions were performed using Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA) and both strands of the resultant products were sequenced using the BigDye® Terminator v1.1 Cycle Sequencing Kit (ThermoFisher Scientific, Waltham, MA, USA) under standard conditions. The labeled products were subjected to electrophoresis on an ABI 3500 Genetic Analyzer sequencing system (ThermoFisher Scientific, Waltham, MA, USA). Electropherograms were analyzed using Sequence Analysis Software version 5.4 (ThermoFisher Scientific, Waltham, MA, USA) and compared to reference sequences using ChromasPro version 1.7.7 (Technelysium, Queensland, Australia). Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequences.

## Results

Over a 42-month period, 200 cases with heterogeneous genetic disorders were enrolled in this study. Among these patients, around 80% (159 samples) were younger than 18 years of age. From the latter, 150 cases were children, including the case of a fetus whose specimen was collected after a terminated pregnancy.

Patients were referred by physicians for presenting with (Table 1): neurodevelopmental disorders (in 39.5% of the cases), neuromuscular disorders (10%), metabolic and mitochondrial disorders (9.5%), renal disorders (5%), hearing disorders (3.5%), isolated epilepsy (3%), bone diseases (2%), leukodystrophy (2%), visual disorders (1%) and other rare diseases referred as "others" in all tables (24.5%). WES was performed on these patients for diagnosis purposes.

Our first analysis yielded a success rate of 49.5%. In other words, genetic diagnosis was established in 99 patients, after the first analysis (Table 2). In order to improve the diagnosis yield, reanalysis of WES data, generated during the first 2 years of this study, was carried out. Reanalysis was performed using new bioinformatics algorithms and was based on the newly established local database, new genes discoveries and additional clinical information for each of the undiagnosed patients. The second analysis allowed the identification of the pathogenic mutations in 13 additional cases (Table 3) corresponding to 6.5% increase in the genetic diagnosis rate, thus leading to an overall success rate of 56%. The 112 patients with established genetic diagnosis included 54 patients with autosomal dominant diseases, 49 with autosomal recessive diseases, and 9 with X-linked diseases. Different types of mutations were detected including small frameshift, nonsense, splice sites, and missense mutations.

There was a trend towards an association between the rate of positive diagnosis and the disease group. Indeed, the highest diagnosis success rate corresponds to the group of hearing and visual disorders (100%), followed by neuromuscular disorders (85%), metabolic and

 Table 1 Distribution of cases between disease groups with the corresponding success rate

Pathologies	Number of patients presenting the pathology	Number of patients with established molecular diagnosis	Percentage of patients with established molecular diagnosis (%)
Neurodevelopmental disorders	79	24	30.4
Neuromuscular disorders	20	17	85
Metabolic and mitochondrial disorders	19	16	84.2
Renal disorders	10	6	60
Hearing disorders	7	7	100
Epilepsy	6	4	66.7
Bone diseases	4	3	75
Leukodystrophy	4	3	75
Visual disorders	2	2	100
Others	49	30	61.2
Total	200	112	56

mitochondrial disorders (84.2%), bone diseases and leukodystrophy (75%), epilepsy (66.7%), others (61.2%), renal disorders (60%) and neurodevelopmental disorders (30.4%) (Table 1).

Of the 136 identified mutated alleles, 66.9% were novel variants at the time of diagnosis.

## Discussion

WES is a relevant, efficient and cost effective genetic diagnostic tool that allows the detection of a wide range of genetic variants including point mutations (missense and nonsense mutations), small deletions and insertions in addition to canonical splicing mutations [15]. However, linking genetic variations to diseases still represents a big challenge in many cases.

Here we report the first study on WES outcome in the Lebanese population. Exome sequencing performed in 200 cases included in our study first yielded a 49.5% overall success rate, which is concordant with other international studies [16]. This rate was variable depending on the disease group. It barely reached 30.4% in some cases such as in neurodevelopmental diseases including intellectual disabilities (ID) and autism spectrum disorders (ASD) but was extended to 100% in the case of some diseases with well-established molecular mechanisms, such as visual and hearing disorders.

In order to improve the diagnostic yield, WES raw data that was generated over the first 2 years were reanalyzed. Repeated WES analysis enabled us to establish the genetic diagnosis, for 13 additional patients who were left undiagnosed, corresponding to around 7% increase in the diagnosis rate. This positive outcome is due to many factors, among which: the development of new annotation and filtering tools (including new bioinformatics variant effect prediction logarithms), the continuous revelation of new genes in addition to the implementation at our research unit of a Lebanese WES database that allowed us to filter out all "private" Lebanese polymorphisms. Apart from these factors, the 2 years of experience in WES analysis were an asset that helped us improve our performance in data interpretation. Here we report some of the lessons learned from our study:

Two monogenic diseases can masquerade as a single entity: the first molecular investigation of both parents (P5 and P6) of two deceased patients presenting with heart failure and achromatopsia did not lead to any success. However, reanalysis helped to identify, in each parent, two heterozygous mutations in *MYL3* and *PDE6C*, responsible for two different conditions: heart defect (OMIM #608751) and achromatopsia (OMIM #613093), respectively. The observation, in a single patient, of multiple "hits" leading to a unique clinical presentation is nowadays becoming more and more acceptable.

Molecular geneticists need to be aware of filtering out homozygous mutations classified, by bioinformatics logarithms, as "heterozygous uncertain" due to poor read depth: A homozygous mutation in *PET100* in the patient P13, classified as heterozygous uncertain by our logarithm was missed in our first WES analysis. Reanalysis allowed the detection of this candidate mutation and Sanger sequencing enabled its confirmation.

Patients from consanguineous families can still present with compound heterozygous mutations: Patients P10 and P95, issued form consanguineous Lebanese families, were for instance shown to carry respectively two compound heterozygous mutations in *MYO15A* responsible for an autosomal recessive type of deafness (OMIM #600316) and in *SPG11* responsible for spastic paraplegia type 11 (OMIM #604360).

De-novo mutations linked to autosomal dominant conditions can occur in patients from consanguineous families: A de novo mutation in GJB3 (p.S199R) involved in hearing loss was detected in patient P66 who is issued from a consanguineous Lebanese family. Jalkh et al. BMC Medical Genomics (2019) 12:11

 Table 2 Clinical and genetic characteristics of families with

 established genetic diagnosis following the first analysis

Affected         Affected           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0           0         0         0	Commyability	Coefficient of remangainity 118 118 With the purper 121	Mode al inheritance avereiling in the poligree AD AL	Pathongs Neuromaniar datalan	Clinical signs	Gene JANN JUNI, JANN JANN H	Manadon pLLINV (LINE-N)	Xippolity Ha
0         +           0         +           0         -           0         -           0         -           0         -           0         +           0         +           0         +           0         +           0         +           0         +           0         +	* ~	134		Neuronacciar deorder	At its years old, absorbed gott work streak dated assume the	3330 (MM_3000M)	ALTONIA MICHO	-
0            0            0            0            0            0            0	* ~	134						162
0            0            0            0            0            0            0	* ~	134		Neurosundar durider	Indianal Africans, psychosoky delay, conhellar atasia, modesic atasia,	LINN PRILING	p.75234 (s.1805-0)	Henry
0 0 0 0 0 0	÷		18		atasia, myochesic atasia, ovelovilar atrophy, orionet Neuroik vekproemi i & ks., atasia, spartic diplogia, chot		*MINT (6-2004)	
· · · · · · · · · · · · · · · · · · ·		with the purper 121		Neuromanolar dasrdas	atmis, speric diplogis, shot constition Thra life degreed from t	CTPTLY (NM, 1889) SCIEGO (NM 1889)	pALINE (CANNER)	Henry Hitz
0 ·			44.	Other: heart disease and a dramminguik	Two lab. docard from beart falser. Our of them processed also adversational	MCJ (SM NON POSIC (SSL INGN)	\$1502 £ 510 C	ilo ile
0 0 0 0	•		14	Ober-Alexan	Abiecos, depignentation of the skir, systegmer, photopholia	200,000,00020	p.8296 (r.895-T) (FXS-16-4)	Composed II
0 0 0 0	•			Normacciar durates	Manufac dyninging	CAPYE (NOLUMINO)	WIT L_MARCH	Corpored
0 + 0 +			AR, da noso	Hurig-director	Disduces at the age of 3 years	DORWI ONE BERRITS	MIT CARDON MERCINING	Fardgook
	+	3.16	44	Horig durity	Mild to serve a deallance	450334 (59,06525)	PASOVICIONENTI PRODUCIONENTI	Corpore I
,		0.05	AR, X field	Numbrolepmental deceder	risenale obspectial delay, occidity, Alex, small Sovheral Neurolaude	A785 (NM_00009)	p3850(16.2070-0)	Honizypti
	-		de nevo	Neurodevelopmental disorder	Normali obspanniał dalar, domortka, microspitały, kostoska ostępia, microspitały, sostępiskał byłkospitacja unije obspaniał byłkospitacja unije	0822 094,01786	p.10098 (c.61109-8)	190
					ambical anay, kuko(orophy			
	-			Meubok donter	Elistend severe dealway, wand face, consulting crisis, successor, actions activity and specials.	2011W-090,00171159	pMILE X-IQ	Ho.
_					scient activity and quarterly, shortaded balls and brod			
					Acrodysomia, inclusted dashlip, assessiv obprovid skity, increased appetite, milt			
	- Inere villend			Tow desay	mamorphily, consider ones, hypotekrim, opeantie field,	AMAD POLISIONOS	p.223A (s.23A-4)	164
					broad base to some, small and short more, optimical more, that marial biologic, antirum ted marries,		,	
					tid fee hypphaie, oper mosth approximer, smill lands, hepledately.			
• •		236	A.	Huring-Storester		(247) (NU-0000) SCOM (200 R040)	#128016.07900-A) #8007916.2000-D	Henr HQ
			AD, de nener	Versiele clepsenial disorder	Neurole-depnental-delay, statural-delay-dynnaryba, ritatianenhole-doct-tank	MICHT (MM, MIPPL3)	p3.386(6/944(s-117),128)	1be
-								
					delay, hypersignal from the white matter, blateral enlargement of the lateral randomater, atomics of		p2196 (c.550-C)	Henry
0 >	- (same vilage)			Versiele eleptonid develor	the conduction, delayed conductions function, areacheold	XXX/1 (XM_00060)		Henry
					regions of the labe		poeto (comant)	
	-		AD, de nevo	Horig-durity	Speaking-Ality, hyposonosis, edil to arrow measuremented dedisors, successful edils	CIM23 INN_02236 MINUA INN 024255	a FART (C. 1970) (A)	Ho Ho
• •			AR.	Metabolic discase in her deceased child	Made symptotic decay is her	\$63033 (00, 1000) \$63033 (00, 1000)	p.5096. p. 1002-T)	Ho.
					Psychosoper Adap, Makend optic amplity, citement scienced (Indian)			
		136	AR, AD	Mastela duelor	compatible with a surrow generalized surrow	CLCVF (NOL_00003)	p79206 (x27844K)	He.
1	1				portextipatio el opinicambellar degeneration, muck Nopy; mitchondric)			l
		18	A8, AD	Real disfunction	Proferoutic hidson	7551 (Not 10100944	#H1030 (r 9840-A)	ilu.
1.				Testas	vanishing white matter, min-merginally, insensity, min-merginally, insensity,	IN STREET, ST.	p.0688.(c.1553-G)	Hene
1		18	4	Louisdy-imply	pageosplaty, encogenhiers, thick hair, hyperseir, becaused appears, developments,	Property OW Intelli	pAITT 8:520-94	Bene
+					oplepty hepitopleannegily Decement children Field			
• •	*	Nili de patrar- 3 M	14.	Other - Epidematibuliesa in their tire deceased (SREE)	know around Imper sub- of the lower log around joints. formation of Merce Area	14842 (901,00027)	0.1709-SMITTC	Ho.
1					to minor physical agery	and a second	- Terrer L	
	· ·		de novo	Neuromandar das der	Psychonoxy dolp, Social same Psychonoxy dolp , indicated	31542 (SM 18844 31542 (SM 38841)	plosity a distance of a second second	ilo ike
	•		AD, de novo AD, AR, de novo *-	Scando-cleptional dioteler	delkienzy annik, dysaetheis, conductor disordier	ACACI INN_00475		Ho.
			bird	Takoy	Tabley Row mercer stead	26A (ML 1885)		Heater
• •	Para-to from the same village		AD, 44 00%, AR	Scatole-adopticital disorder	shormalitics, hore pain , psychometer discretes, speaking	75781 (MC, HINN)	p.8216C (c.852C=T)	Ho.
		1028	41	Direct	britaites, topoptus Pyritaite-dependent spikpey.	404741-094-001103	10050 70110	Hene
o >			AD	Kend dyslimites	Polycyste lakey drama, Yolycyste lakey drama, youd curts	2000 (50, 1966)	0.30247-0	Ho.
o +		1.94	44	Neuromanolier daardee	Pophenets delay, march weatness, classific (PK, march for mellic)	03662 (00,0000)	plittin o anno Ao	Hene
	Pare-to from the		4	Meldule design Alexand Fills design	Hepstophnomogaly, tocorow computery atlocked, atmosph	INFO FOR OOM	ADDREATINGS	Henry
	same village		10 do may Thebad	Intelected	vite tetra spit, spininelog: cleary sol spit- Figgs bits, hypotek,	KAL ON OWITH		Mania and
• •	-		AR.	Road dy-function	moccie white mater canal Read-by-function	192831 (NM, 109842)	pq043*6240C-0	Ho.
	-		AD, de novo	Number-dependent disorder	Psychosofie delay dyonogital proming eyes, stangular lucz,	0054 (MIL 1898)	p.60210 to 18020-42	Ho.
			AD, da neve	Neurode-eleptronial deceder	Proburator delay, atesia, Ingunaria, muccinic episper-	ALC2/F (POL 000716.2)	9.029.0040	Ha
		18	ű.	Horig danke	Deallane Deallane Cardec audioraesions, oplopsy.	0007 (ML (MD4)	PATIENT REPORT OF	Flore
5			AR.		at such that is a set of the part of the	\$24144 (SML)00000	p.0389* (c.9250+G)	Hene
o .	Para-to floor the same village		40	Manufacture and Acades	handrade: http://www.	AND AN EVEN	A DECOMPANY	10.
5	Para-to them the same village		AD AD, Melici	Vermiteratorienti disordar Vermiteratopienti disordar	Amountain International Proclammer dates opening delay legenetering, michanial	1079 (SN, 0049)	pHINE 0.00070	Ho Honigger
	rana verda	1.8	AD AD-Xileiol AR	Vender-demont dender Senste depressi dender Neurstandig dender	Americania Marchalania Prychonosti Marchalania Prychonosti div, speking debity Marcalit vasilanis, fowers test pestire, progressive	MPR 000 82836	ATTROUBER ATTROUGHER A	Ho Honiques Hene
	une vage	18		Normleveleneerid donke Normlevelepeerid donke Normuole donke Oder Uder palone	diability	477 (NIL 828)		
			A.	Noromacilar diseder	diability	1070-000-0000 2701-000,00000 2102253-000,0000	£902.0380-0	Hene
0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -	· · · ·		44. 44.	Non-muscular diserter Other Uniter syndrose	dashilar Macalat vaslanas, Govers tea peaker, progressire vaslane dificulter Yanal and haring disorders, photoplate	1079 AN E276 AT (10,000)	pYRP (c.880C-A) pG8815-gc.341MAG	Hene Hene Hu
0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -	-		AR AR AD-A: News, X Micel	Norremotie dorder Oder Uder Uder solore Norderdeprend dorder	dashiby Maculat walatan. Govern two policy programs walata difference paraphila Psychosotra delay, spatialaj delay, alta antego delay, spilopo, logarikata, sudora Macujahatan, Auccuratej vand anato in beli yen, astanat Narazka Alexandra Jane Kr.	1022/00182000 1022052-000_00000 1022052-000_00000 1022052-000_00000 1022052-000_00000	p230%63880%6 p6883562364880 p88856236456	Hene Hene
0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -	· · · ·		AR AR AD-A: News, X Micel	Norremotie dorder Oder Uder Uder solore Norderdeprend dorder	dashiby Maculat walatan. Govern two policy programs walata difference paraphila Psychosotra delay, spatialaj delay, alta antego delay, spilopo, logarikata, sudora Macujahatan, Auccuratej vand anato in beli yen, astanat Narazka Alexandra Jane Kr.	1022/00182000 1022052-000_00000 1022052-000_00000 1022052-000_00000 1022052-000_00000	p230%63880%6 p6883562364880 p88856236456	Hene Hene Hu
3         -           3         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -           0         -	· · · · · · · · · · · · · · · · · · ·		AA. AA. AD. dr. 1000, X Mool AB, AO. dr. 1000, X Model AD, dr. 1000, X Model AB, dr. 1000, X Model AB.	Neuromodie diordet Ottet Unite spatione Neurole-dependet diorder Otter Margielichen Neurole-dependet diorder Neurole-dependet diorder Neuronodie diorder	diable Maryaki washana, Gowan san pashin, pagmatar washin difkuda Yinal ad haring disektor, phosphola Psychonater dify, spaking dela, nil amogandan, apikaya bayarkaty, sodani	3070/081 0395 2021 (201,0000) 2020/201,000,0000 2020/201,000,0000 2020/201,000,0000 2020/201,000,0000 2020/201,000,0000 2020/201,000,0000	bT80.6 P00.00 brain P100.00 brain P100.00 br	Here Here Ho Ho Here Here
	· · · · · · · · · · · · · · · · · · ·		AR AR AR, de serve, X block AR, de serve, X block	Normander devide Orter Untergehone Verstehengenstell devide Orter Margeholen Normander devide Normander devide Normander devide Normander devide	dashiby Maculat walatan. Govern two policy programs walata difference paraphila Psychosotra delay, spatialaj delay, alta antego delay, spilopo, logarikata, sudora Macujahatan, Auccuratej vand anato in beli yen, astanat Narazka Alexandra Jane Kr.	5070 / 508 / 51976 / 721 / 504 (5080) / 721	PLOR 0100-09 PLOR 0100-09 PLOR 0100-09 PLOR 01000-09 PLOR 01000-09 PLOR 01000-09 PLOR 01000-09 PLOR 01000-09 PLOR 01000-09 PLOR 01000-09 PLOR 0100-09 PLOR 0100	Here Here Ha Ha Here Here Here Here
	· · · · · · · · · · · · · · · · · · ·		AR AR AD-de sons, X Mod AR, AD, de sons, XMAR AD, de sons, XMAR AR AR	Neuromodie dierdet Oder Unter syndrose Verender-deprecent dierder Oder: Morgebolten Verender-deprecent dierder Verender-deprecent dierder Neuromodie dierder Neuromodie dierder	dashiby Maculat walatan. Govern two policy programs walata difference paraphila Psychosotra delay, spatialaj delay, alta antego delay, spilopo, logarikata, sudora Macujahatan, Auccuratej vand anato in beli yen, astanat Narazka Alexandra Jane Kr.	3070-030 10396 - 020 (100,00009) - 0200 (100,00009) - 02007 (100,00009) - 02007 (100,00005) - 02007 (100,00005) - 0200 (100,00009) - 0200 (100,0009) - 0200 (100,0009)	<ul> <li>р.730° 0.380°-66</li> <li>р.61815 0.394560</li> <li>р.01826 0.394560</li> <li>р.01826 0.3946 0.0</li> <li>р.01826 0.3946 0.0</li> <li>р.1386 0.3967 0.0</li> <li>р.1386 0.3967 0.0</li> <li>р.1386 0.3967 0.0</li> </ul>	Here Here Ho Ho Here Here
	· · · · · · · · · · · · · · · · · · ·		AR AR AR, de serve, X block AR, de serve, X block	Normander devide Orter Untergehone Verstehengenstell devide Orter Margeholen Normander devide Normander devide Normander devide Normander devide	dashiby Maculat walatan. Govern two policy programs walata difference paraphila Psychosotra delay, spatialaj delay, alta antego delay, spilopo, logarikata, sudora Macujahatan, Auccuratej vand anato in beli yen, astanat Narazka Alexandra Jane Kr.	5070 / 508 / 51976 / 721 / 504 (5080) / 721	1709/03800-06 2008/5-559465 2008/5-559465 2008/5-55940-0 2008/5-5090-0 2008/5-500-0 2008/	Hene Hene He He Hene Hene Hene Heneyper He Heneyper Heney Heney Heney Heney
	ner vage		AA. AB. AB. AD. Access AR. Access Water AR. Access Water AR. Access Water AR. Access Water AR. Access Water AR. Access Market AR. Access Market ACC Access Market ACC ACCES ACCESS MARKET ACCESS M	Normander devide Orter Untergehone Verstehengenstell devide Orter Margeholen Normander devide Normander devide Normander devide Normander devide	dashiby Maculat walatan. Govern two policy programs walata difference paraphila Psychosotra delay, spatialaj delay, alta antego delay, spilopo, logarikata, sudora Macujahatan, Auccuratej vand anato in beli yen, astanat Narazka Alexandra Jane Kr.	MOVAM BINN     MOVAM BINN     MOVAM BINN     MOVAMBIN     MOVAMBI	φ-200,9 PRG 4     φ-200,9 PRG 4     φ-200,0 PRG 4     φ-7055,0 200,0 q     φ-7055,0	Hens Hens He Hers Hes Hens Hens Hens Hens Hens Hens Hens
	· · · · · · · · · · · · · · · · · · ·		AR AR AR AR AR AR AC ACON AR AR AC ACON AR AR AC ACON AR AR AR AR AR AR AR AR AR AR AR AR AR	Neuromodie deroko Orke Oder enderom Versich obereit derok Oder Ansteinen Neuroschereit derok Neuroschereit derok Neuroschereit derok Neuroschereit derok Neuroschereit Neuroschereit Oder Gemeinscher Versicherten Neuroschereit N	dashiby Maculat walatan. Govern two policy programs walata difference paraphila Psychosotra delay, spatialaj delay, alta antego delay, spilopo, logarikata, sudora Macujahatan, Auccuratej vand anato in beli yen, astanat Narazka Alexandra Jane Kr.	MOVING 6249     APE (54,0000)     APE (54,00000)     APE (54,0000)     APE (54,0000)     APE (54,0000)     APE (54,00000)     APE (54,000000)     APE (54,000000)     APE (54,0000000)     APE (54,00000000)     APE (54,000000000)     APE (54,000000000000000000000000000000000000	42-2003/2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-200	Hens Hun Hu Hun Hun Hun Hun Hun Hun Hun Hun
	r	28 28	AA. AB. AB. AD. Access AR. Access Water AR. Access Water AR. Access Water AR. Access Water AR. Access Water AR. Access Market AR. Access Market ACC Access Market ACC ACCES ACCESS MARKET ACCESS M	Normsocke docks Other Unite stations Veneto-dependent diorder Other Morpholetik Normsockensent diorder Normsockensent diorder Normsocken diorder Normsocken diorder Normsocken diorder Normsocken diorder Normsockensent Normsockensent Normsockensent Normsockensent Normsockensent Normsockensent Normsockensent Normsockensent Northermockensent Statiotak darer	Could be added to a second secon	MOVAM BINN     MOVAM BINN     MOVAM BINN     MOVAMBIN     MOVAMBI	φ-200,9 PRG 4     φ-200,9 PRG 4     φ-200,0 PRG 4     φ-7055,0 200,0 q     φ-7055,0	Hens Hens He Hers Hes Hens Hens Hens Hens Hens Hens Hens
	ner vage		AR AD, Ar sees, X Mod AD, AD, et sees, X Mod AD, AD, AD, AC news, X Mod AD, Ar news, X Mod AR AR AR AR AR AR AR AR AR AR AR AR AR	Neuromodie deroko Orke Oder enderom Versich obereit derok Oder Ansteinen Neuroschereit derok Neuroschereit derok Neuroschereit derok Neuroschereit derok Neuroschereit Neuroschereit Oder Gemeinscher Versicherten Neuroschereit N	Could be address of the second s	MOVING 6249     APE (54,0000)     APE (54,00000)     APE (54,0000)     APE (54,0000)     APE (54,0000)     APE (54,00000)     APE (54,000000)     APE (54,000000)     APE (54,0000000)     APE (54,00000000)     APE (54,000000000)     APE (54,000000000000000000000000000000000000	42-2003/2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-2003/2003/ 42-200	Hens Hun Hu Hun Hun Hun Hun Hun Hun Hun Hun
	r	28 28	AR AR AR AR was X Mod MA AR was X Mod AR Ar was X Mod AR AR Ar was X Mod AR AR AR AR AR AR AR AR AR AR AR AR AR	Normania de oto Obst. Una cuelara Nando-operativa de la companya Obst. Nando-operativa Obst. Nando-operativa Nando-operativa Nando-operativa Nando-operativa Obst. Una de la companya Obst. Una de la companya Nando-operativa Obst. Una de la companya Nando-operativa Obst. Una de la companya Nando-operativa Nando-operativa Nando-operativa Obst. Una de la companya Nando-operativa Nand	Could be added to a second secon	MOV AND INDEX     //// (NV AND INDEX     /// (NV AND INDEX     // (NV AND     // (NV AN	<ul> <li>γ2029 - 0.8802 - 4</li> <li>γ2029 - 0.8802 - 4</li> <li>γ2029 - 4.8814 - 4</li> </ul>	Hens Hens Dr Dr Harkwels Hens Hens Hens Hens Hens Hens Hens Hen
	r	28 28	AK AK AB, dr. mm, X Mol AB, AD, de novo AB, dr. mov. Ninkel AB, dr. mov. B, and AB, dr	Norminoli dede Otto Liko opeler Versichelgeneit der Otto Angeler Versichelgeneit der Versichelgeneit der V	Ander     A	Start 200 (2004)     Star	P2091-0.880-0.0 pc8883-0.588440 p8885-0.5884-0.0 p28885-0.5884-0.0 p28885-0.5884-0.0 p2888-0.5884-0.0 p2888-0.5884-0.0 p2888-0.5894-0.0 p2888-0.58940 p2888-0.58940 p2888-0.58940 p2888-0.58940 p2888-0.58940 p2888-0.58940 p2888-0.58940 p2888-0.58940	Here Here
	r	28 28	AK AK AB, dr. mm, X Mol AB, AD, de novo AB, dr. mov. Ninkel AB, dr. mov. B, and AB, dr	Normania de da f Orch Lian gentre Sectore dependente Orch Angeler Sectore de Sectore de Sectore Sectore de Sectore de Sectore Normania de Sectore Sectore de Sectore de Sectore de Sectore Sectore de Sectore de Sectore de Sectore Sectore de Sectore de Sectore de Sectore de Sectore de Sectore de Sectore Sectore de Sectore	Could be added to a second secon		۵٬۵۹۹ / ۵٬۵۹۹ / ۹۵٬۷۹۹ / ۹۵٬۷۹۹ / ۹۵٬۷۹۹ / ۹۵٬۹	Been Been Do Do Do Been Been Been Been Been Been Been Bee
	Processing	136 13 5 36 5 36 herpemer 2 36	AR AD, dr sows, X block AB, AD, de sows, X block AB, de sows, Stated AB, de sows, Stated AB, de sows, Stated AB, de sows, AB, D, Stated AB, D, X, D, Stated	Normania devida Obel Libo catalar Obel Alexandro devide Santa deposite devide Santa deposite devide Santa devide devide Normania devide Normania devide Santa devide devide Santa devide devide Santa devide devide Santa devide devide devide Santa devide devide devide Santa devide devide devide devide Santa devide devide devide devide devide Normania devide de	Ander     A	ANY-OLD LEASE     APET (VOL, MONT)     APET (V	γ200° 4, 800-56     γ200° 4, 800-56     γ200° 4, 500-66     γ200° 4, 500-67	Been Been Do Do Do Do Do Heen Been Been Been Been Been Been Been
	Preco from Pr	236 	AE. AB. AB. AD. de nov. X block AB. AD. de nov. Nuted AB. de nov. Nuted AB. AR. O. Shidol AR. AR. O. Shidol AR. D. Shidol de nov. AR. D. Shidol de nov. AR.	Semme in Archi Dec. Una compare Semicological Archives Semicological			1990%,0000, 1990%	Hum Hum Hu Hu Hu Hum Hu Hum Hu Hum Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu
	Para o Dan fe	236 	AK AR AR AR AR wee, X Musi AR AR AR wood Natural AR AR WOOD Natural AR AR AR AR AR AR AR AR AR AR AR AR AR	Second de Arché Dec Lora contra Una de Lora contra Una de Lora contra Una de Lora contra Una de Lora contra Second de Arché Second de Arché Se	Control of the second secon		μ200 - (μ00 - μ)     μ000 - μ - μ000 - μ     μ000 - μ - μ000 - μ     μ000 - μ - μ000 - μ     μ000 - μ     μ000 - μ000 - μ     μ     μ000 - μ     μ	Been Been Boot Boot Been Been Been Been Been Been Been Bee
	Preco from Pr	236 	AE. AB. AB. AD. de nov. X block AB. AD. de nov. Nuted AB. de nov. Nuted AB. AR. O. Shidol AR. AR. O. Shidol AR. D. Shidol de nov. AR. D. Shidol de nov. AR.	Semme in Archi Dec. Una compare Semicological Archives Semicological			1990%,0000, 1990%	Hum Hum Hu Hu Hu Hum Hu Hum Hu Hum Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu Hu
	in my	236 	48. 48. 49. de non. Stated 40. de non. Stated 40. de non. Stated 40. de non. Stated 40. de non. 40. de	Annunde ande Decision and an annunde ander Mainte dependent ander Mainte dependent ander Mainte ander ander Mainte ander ander Mainte ander ander Mainte ander ander Mainte ander ander Mainte ander Mainte Mainte ander Mainte ander Mainte Mainte ander Mainte ander Mainte ander Ma		ALT OF ALL AND A ALT OF ALL AND A ALL AND A ALL AND A ALL AND A ALL AND A ALL AND A ALL AND A AL	100%.0000 100%.00000 100%.00000 100%.0000 100%.0000 100%.0000 100%.0000	Home Home Dry Harsteen Home Home Home Home Home Home Home Home
	in my	236 	AR. AR. AR. AR. (A new, X block AR. (AR (new)) AR. (AR (new)) AR. (AR (new)) AR. (AR (new)) AR. (NR (N here)) AR. (NR (N here)) AR. (NR (N here)) (NR (N here	Ansame de André Statistica de Carlos de Santa Marcine de Carlos de Carlos Carlos de Carlos de Carlos Carlos de Carlos de Carlos Carlos de Carlos de Carlos Carlos de Carlos de Carlos Carlos de Carlos Carlos de Carlos Carlos de C	Control of the second secon		улагча моно) (1979 ч. моно)	Hear Hear Horsen Hersen Hear Hear Hear Hear Hear Hear Hear Hear
	in my	236 	AR. AR. AR. AR. (A new, X block AR. (AR (new)) AR. (AR (new)) AR. (AR (new)) AR. (AR (new)) AR. (NR (N here)) AR. (NR (N here)) AR. (NR (N here)) (NR (N here	Norman de André Deut Lang contra Nació elegant datas Unació elegant datas Unació elegant datas Unació elegantes Nación deutos Nación deutos Na			PARA (1996)     PARA (19	Hore Hore
	in my	1 16 18 10 10 10 10 10 10 10 10 10 10	А А А, В, секона А, В, секона В, В, секона А В, С. Секона А В, С. Секона А В, С.	Second a devid Decidence of the second Second and the second and the Uncollection of the second and the Uncollection of the second and the Uncollection of the second and the Second and the second and the second and the Second and the second and the second and the Second and t		ADTO DU AL MARE      ADTO DU AL MARE     ADTO DU AL MARE      ADTO DU AL MARE	γ20 <sup>2</sup> - (100 <sup>2</sup> )      γ20 <sup>2</sup> - (100 <sup>2</sup> )      γ20 <sup>2</sup> - (100 <sup></sup>	Home Day Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy
		1 16 18 10 10 10 10 10 10 10 10 10 10	А 3. 4. и чест 1. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.	Security of a set of Security of Security			110° - 100° - 100° - 1 200° - 200° - 2 200° - 200° - 2 200° - 200° - 2 200° - 200° - 2 200° - 2 200	Home Day Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy Dy
		1 16 18 10 10 10 10 10 10 10 10 10 10	А А А, 0, 100 40, 0, 100 40, 0 но 100 40, 0 но 100 40 40 40 40 40 40 40 40 40	Summarka karda Distribution david Sumichican david Sumichican david Summarka davi			1130 - 1140 - 1140 - 1     1140 - 1     1140 - 1	Home Home 192 193 194 Home Hom
		1 16 18 10 10 10 10 10 10 10 10 10 10	10 30 30 30 30 30 30 30 30 30 3	Security of a set of Security of Security			(1995) 1000 (0)     (1995) 1000 (0)	Home Home 192 193 194 Home Hom
		1 16 18 10 10 10 10 10 10 10 10 10 10	А А В 4 ин 51 ни В 4 ин 51	Second and a second a			1199 - 119	Hore Horizon Harrison
		13 	А А А А А А А А А А А А А А	Summaria and Decision of the second second Second second second second second Second second second second second Second second second second second second second Second second second second second second second Second second second second second second second second Second second second second second second second second Second second s			(110) - 100 - 1     (110) - 100 - 1	Hore Hore Hore Hore Hore Hore Hore Hore
		13 	А А А А А А А А А А А А А А	Second a dark On Color and a Second and a Color and a				Hore Hore Data Hore Hore Hore Hore Hore Hore Hore Hore
		13 	А А В в но 16 нес. 16 и нес. 16 нес. 16 и нес. 16	Norman de André Ober (Alex dents) Norman de André Norman de Andréa Norman		AND COLUMNS COLOR COLUMNS COLOR COLUMNS COLUMN	Hornester     Harris Santas     Harris San	Hore Hore Hore Hore Hore Hore Hore Hore
		13 	А А А А А А А А А А А А А А	Second a dark On Color and a Second and a Color and a				Hore Hore 132 132 132 132 132 132 132 132 132 132
		13 	А А А А А А А А А А А А А А	Norman de André Serie (1999) en anti- serie (1999) en anti- (1999) en anti-				Hore Hore Data Hore Hore Hore Hore Hore Hore Hore Hore
		13 	А А А 4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0	<ul> <li>Second and a second a seco</li></ul>			Hard a service     Hard a s	Book Book Book Book Book Book Book Book
		13 	<ul> <li>М</li> <li>А</li> <li>А</li></ul>	Norman de André Serie (1999) en anti- serie (1999) en anti- (1999) en anti-				Born           Born           10
		13 	ій А А Ві ()) боло чало Ві ()) Ві ()) боло чало Ві ()) Ві ()	Second and a second a				1000           1000           100
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<ul> <li>10</li> <li>11</li> <li>12</li> <li>13</li> <li>14</li> <li>14</li> <li>15</li> <li>15</li> <li>16</li> <li1< td=""><td>Summarka kark Disciolegica (Seconda Seconda Se</td><td></td><td></td><td></td><td>1000           1000           100</td></li1<></ul>	Summarka kark Disciolegica (Seconda Seconda Se				1000           1000           100
		13 	ій А А Ві ()) боло чало Ві ()) Ві ()) боло чало Ві ()) Ві ()	Second and a second a				1000           1000           100
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	<ul> <li>10</li> <li>11</li> <li>12</li> <li>13</li> <li>14</li> <li>14</li> <li>15</li> <li>15</li> <li>16</li> <li1< td=""><td>Summarka kark Disciolegica (Seconda Seconda Se</td><td></td><td></td><td></td><td>1000           1000           100</td></li1<></ul>	Summarka kark Disciolegica (Seconda Seconda Se				1000           1000           100
			<ul> <li>А</li> <li>А</li></ul>	Neuron de André Selection de And				Horr           Hor     <
		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		Norman de André Serie (Norman de André Serie			Hard a setting     Hard a	1000           1100           120
		23 24 		Neuron de André Sol (Con Carlos) Neuron de Carlos (Con Carlos) Neuron de Carlos) Neuron de Carlos Neuron de				Element     E
				Neuron de André Selection de And			Hard a setting     Hard a	
		23 24 		Neuron de André Selection de And				Base
		23 24 		Neuron de André Sol (Con Carlos) Neuron de Carlos (Con Carlos) Neuron de Carlos) Neuron de Carlos Neuron de				Base
		23 24 		Second and a second a				Base
	· · ·			·         ·	·         ·	Image: set of the se	i         i	I         I

AD Autosomal dominant, AR Autosomal recessive, Htz Heterozygous, Homoz Homozygous Variable Expressivity and incomplete penetrance of some diseases might mislead the choice of the filtering strategy: Patient P94 who was expected to carry a de novo mutation, was found to have a hemizygous mutation (p.E1204G) in SHROOM4, inherited from his mother who shares with him milder clinical signs.

Pathogenic mutations with a high frequency in a population exist! Filtering out common variants can be risky in the case of genetic disorders that are frequent in a population: In patient P87 presenting with G6PD deficiency, a disease frequently seen in the Lebanese population, WES reanalysis led to the identification of a pathogenic mutation in G6PD (p.S188F) that is present in high frequency (greater than 1%) in several arab populations [17].

WES has technical limitations: Large deletions encompassing candidate genes were detected by CGH arrays in two patients (not included in the study), who were left undiagnosed by WES.

WES coverage data might, in some cases, enable the detection of gene deletion: NPHP1 gene coverage was for instance equal to zero in patient P67 who presented with Joubert syndrome. This gene was fully covered in other patients run on the same sequencing chip. Owing to the potential involvement of the gene in the disease, CGH array was performed and a homozygous deletion encompassing the entire NPHP1 sequence was confirmed, thus explaining the clinical presentation.

# Last but not least,

Communication between clinicians and geneticists is the ultimate key for genetic diagnostics success: In our first WES analysis, genetic diagnostic was not established for the patient P106 who was referred to our center as presenting with Bartter syndrome. While following up on all undiagnosed cases during our WES reanalysis, a pathogenic mutation in *SLC9A2* (p.F82 L) was highlighted and communicated to the physician who re-evaluated the patient and modified the initial diagnosis to congenital chloride diarrhea, known to result from mutations in *SLC9A2* [18].

On the other hand, failure of genetic diagnostics in the remaining patients can be due to several factors: i) the clinical and genetic heterogeneity of some entities: More than 1000 genes are for instance linked to ASD, thus making genetic diagnostics very challenging (https://gen e.sfari.org/database/human-gene/); ii) the detection in isolated cases of private mutations whose pathogenicity is hard to be demonstrated in addition to iii) purely technical limitations associated with WES: Some bioinformatics pipelines are for example unable to detect CNVs (Copy Number Variation), rearrangements or triplet expansions. Homopolymers can for instance be miscalled, thus generating false positive variants. Furthermore, lack of coverage of coding regions

Patient code	Actuel age in years	Affected	Consanguinity	Coefficient of consanguinity	Mode of inheritance according to the pedigree	Pathology	Clinical signs	Gene	Mutation	Zygosity				
P100	11-20	+	+	1/32	AR	Neurodevelopmental disorder	Mild psychomotor delay, vitiligo,	IVD (NM 002225)	p.S281R (c.841A>C)	Homo				
1 100	11 20			1102	m	Treatode verspinental aborder	essential tremor	FASTKD2 (NM 014929)	p.R358* (c.1072C>T)	Homo				
P101 0-10	+	_		AD, de novo, Xlinked	Neurodevelopmental disorder	Psychomotor delay, developmental delay, microcephaly, retrognathism,	ALDH18A1 (NM_002860.3)	c.2207-3C>T	Htz					
					testicular ectopia, dysmorphia	ITPR1 (NM_002222.5)	(c.5164+4C>T	Htz						
P102	51-60	+	+		AD	Neuromuscular disorder	Ataxic walk, dystonia, tremor, dysgraphia	ATXN3 (NM_004993)	p.G306fs (c.915_916ins(CAG) 13)	Htz				
P103	11-20	+	+	1/32	AR	Neuromuscular disorder	Bilateral piramydal syndrome, muscular weakness	<i>TGM6</i> (NM_198994)	p.R342W (c.1024C>T)	Htz				
P104	P104 0-10 +	+	-		AR	Neurodevelopmental disorder	Psychomotor delay, convulsive crisis, hypotonia, excessive	NARS2 (NM_024678)	p.M1fs (c.1_2insG)	Compound Htz				
					weight, tongue thrust	· · ·	p.P20H (c.59C>A)	1						
P105	P105 0-10 +	_	_	de novo	Leukodystrophy / Other: ceroid	Mild psychomotor delay, speaking delay, convulsive crisis,	SLC2A1 (NM_006516)	p.S82Y (c.245C>A)	Htz					
									lipofuscinosis	lipofuscinosis	ataxia, leukodystrophy, hypotonia, talking regression	DYNC1H1 (NM_001376)	p.N4579I (c.1373A>T)	Htz
P106	0-10	+	+	1/128	AR	Renal disease (tubulopathy). Other : congenital osmotic diarrhea	Watery diarrhea, reccurent thrombocytopenia, anemia, neutropenia	SLC9A2 (NM_003048)	p.F82L (c.244T>C)	Htz				
P107	0-10	+	+	1/32	AR	Bone disease	Hypertelorism, short nose, short neck, bowed femur, bowing bones, wide metaphysis	NALCN (NM_052867)	p.1523V (c.1567A>G)	Homo				
P108	0-10	+	+	1/16	AR	Other : ophtalmological disorders	Leber, bilateral blindness	FZD4 (NM 012193)	p.P254fs (c.762delC)	Htz				
P109	31-40	+	+	1/16	AR	Neuromuscular disorder	Dystonia, scoliosis	SPR (NM_003124)	p.P87H (c.260C>A)	Homo				
P110	0-10	+	- (same village)		AR, de novo, X linked	Neurodevelopmental disorder, other : optical neuropathy	Encephalitis, optique neuropathy, epilepsy, hypotonia, convulsive crisis	<i>SLC9A6</i> (NM_006359)	p.V419F (c.1255G>T)	Hemizygote				
P111	0-10	+	-		X linked, de novo	Neuromuscular disorder	Round face, forehead hump, psychomotor delay	COL1A2 (NM_000089)	p.D933N (c.2797G>A)	Htz				
P112	0-10	+	-		AD, de novo, X linked	Other: connective tissu disease	Hypotonia, aplastic nose, ocular edema, progeroid aspect, narrow thorax, microretrognathism, thick hair, small mouth, cutis laxa (abdominal), dystrophy, curved oesophagus, hyperplasia of the toe nails, pes cavus	WRN (NM_000553)	p.K32R (c.95A>G)	Htz				

Table 3 Clinical and genetic characteristics of the 13 additional cases with established genetic diagnosis after reanalysis

AD Autosomal dominant, AR Autosomal recessive, Htz Heterozygous, Homoz Homozygous.

(inefficient capture of regions rich in GC or bad read depth) and misalignment of reads to the reference sequence are all factors that can occur and lead to false negatives [19, 20].

#### Conclusion

In conclusion, WES allowed a rapid and cost effective identification of the molecular bases of heterogeneous genetic disorders in the Lebanese population. Our study yielded an overall success rate of 56%, of which around 7% is due to data reanalysis, thus pinpointing the utility of WES reanalysis that should take into consideration the updates in bioinformatics logarithms/annotation tools, novel genetic findings in addition to the occurrence in patients of new clinical manifestations.

Undiagnosed patients need to undergo further molecular investigation. For these cases, Whole Genome Sequencing (WGS) can be performed in order to enhance coverage performance and to detect non-coding mutations (variants modifying gene expression or affecting cryptic splice sites) and structural variations including big insertions and deletions. However, this approach remains laborious and very costly.

On the other hand, current genetic diagnosis studies focuses on the protein-coding regions and ignores the vast majority of non-coding regulating elements such us non-coding RNAs. We believe that the recent advances in the fields of computational biology and experimental technology will allow a better characterization of these elements, which might enable their integration in similar studies in the future.

Altogether, the outstanding improvement in highthroughput sequencing techniques will enable the establishment of low-cost genetic diagnostics, the identification of novel genes and the elucidation of physiological mechanisms, all driving towards personalized medicine.

#### Abbreviations

AD: Autosomal dominant; AR: Autosomal recessive; CGH: Comparative Genome Hybridization; CNVs: Copy number variations; NGS: Next-generation sequencing; WES: Whole-exome sequencing; WGS: Whole-genome sequencing

#### Acknowledgements

We express our deepest gratitude and sympathy to the families for their full cooperation throughout the study.

#### Funding

This work (samples collection, analysis, and interpretation of data) was supported by grants from Saint Joseph University, Beirut, Lebanon.

#### Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author upon a reasonable request.

#### Authors' contributions

NJ, CyM and EC conceived, designed the study, performed data interpretation and wrote the manuscript. SC, ZH, NH, JAG, RG and NS conducted the experiments and performed data analysis. EF, JPD and VD conducted acquisition and bioinformatics analysis of the raw data. AF, CDK,

#### Ethics approval and consent to participate

Approval to conduct the study was obtained from the Ethics Committee of Saint Joseph University, Beirut, Lebanon (Reference: FM327). All patients, parents or legal guardians signed an informed consent for participation and sample collection.

#### Consent for publication

All patients, parents or legal guardians signed an informed consent for data publication.

#### **Competing interests**

The authors declare that they have no competing interests.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Author details

<sup>1</sup>Unité de Génétique Médicale, Faculté de Médecine, Campus De l'innovation et du sport, Université Saint-Joseph, rue de Damas, Beirut, Lebanon. <sup>2</sup>Service de technologie de l'information, Saint Joseph University, Beirut, Lebanon. <sup>3</sup>Neuropediatrics Department, Lebanese University, Beirut, Lebanon. <sup>4</sup>Division of Pediatrics, Hotel Dieu de France Hospital, Beirut, Lebanon. <sup>5</sup>Department of Pediatrics Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. <sup>6</sup>Department of Pediatrics, Makassed General Hospital, Beirut, Lebanon. <sup>7</sup>Department of Otolaryngology-Head and Neck Surgery, Hotel Dieu de France Hospital, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. <sup>8</sup>Pediatric Neurometabolic Unit, Saint George University Medical Center, Beyrouth, Lebanon. <sup>9</sup>Department of Oncology, Hammoud Hospital University Medical Center, Saida, Lebanon. <sup>10</sup>Department of Pediatrics, Notre Dame De Secours University Hospital, Byblos, Lebanon. <sup>11</sup>Department of Pediatrics, Chtoura Hospital, Chtoura, Lebanon. <sup>12</sup>Unité de Génétique Médicale, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon. <sup>13</sup>Institut Jérôme Lejeune, Paris, France. <sup>14</sup>Aix Marseille Univ, Inserm, MMG, U 1251 Marseille, France.

#### Received: 27 July 2018 Accepted: 11 January 2019 Published online: 21 January 2019

#### References

- Green ED, Guyer MS. National Human Genome Research Institute. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011; 470:204–13.
- Soden SE, Saunders CJ, Willig LK, Farrow EG, Smith LD, Petrikin JE, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014;6:265ra168.
- Bonnefond A, Durand E, Sand O, De Graeve F, Gallina S, Busiah K, et al. Molecular diagnosis of neonatal diabetes mellitus using next-generation sequencing of the whole exome. PLoS One. 2010;5:e13630.
- Dixon-Salazar TJ, Silhavy JL, Udpa N, Schroth J, Bielas S, Schaffer AE, et al. Exome sequencing can improve diagnosis and alter patient management. Sci Transl Med. 2012;4:138ra78.
- Ng SB, Turner EH, Robertson PD, Flygare SD, Bigham AW, Lee C, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009;461:272–6.
- Maddalena A, Bale S, Das S, Grody W, Richards S, ACMG Laboratory Quality Assurance Committee. Technical standards and guidelines: molecular genetic testing for ultra-rare disorders. Genet Med. 2005;7:571–83.
- Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. 2008;10:294–300.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
- Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, Cooper DN, et al. Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinforma Oxf Engl. 2009;25:2744–50.

- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing nextgeneration DNA sequencing data. Genome Res. 2010;20:1297–303.
- 11. Li H, Durbin R. Fast and accurate short read alignment with burrowswheeler transform. Bioinforma Oxf Engl. 2009;25:1754–60.
- DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491–8.
- Desvignes J-P, Bartoli M, Delague V, Krahn M, Miltgen M, Béroud C, et al. VarAFT: a variant annotation and filtration system for human next generation sequencing data. Nucleic Acids Res. 2018;46(W1):W545-W553.
- Zhu X, Petrovski S, Xie P, Ruzzo EK, Lu Y-F, McSweeney KM, et al. Wholeexome sequencing in undiagnosed genetic diseases: interpreting 119 trios. Genet Med. 2015;17:774–81.
- Kryukov GV, Shpunt A, Stamatoyannopoulos JA, Sunyaev SR. Power of deep, all-exon resequencing for discovery of human trait genes. Proc Natl Acad Sci U S A. 2009;106:3871–6.
- Yavarna T, Al-Dewik N, Al-Mureikhi M, Ali R, Al-Mesaifri F, Mahmoud L, et al. High diagnostic yield of clinical exome sequencing in middle eastern patients with Mendelian disorders. Hum Genet. 2015;134:967–80.
- Doss CGP, Alasmar DR, Bux RI, Sneha P, Bakhsh FD, Al-Azwani I, et al. Genetic epidemiology of Glucose-6-phosphate dehydrogenase deficiency in the Arab world. Sci Rep. 2016;6:37284.
- Thiagarajah JR, Donowitz M, Verkman AS. Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol. 2015;12:446–57.
- Ku C-S, Cooper DN, Polychronakos C, Naidoo N, Wu M, Soong R. Exome sequencing: dual role as a discovery and diagnostic tool. Ann Neurol. 2012; 71:5–14.
- 20. Singleton AB. Exome sequencing: a transformative technology. Lancet Neurol. 2011;10:942–6.

#### Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- · thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

#### At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

